Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.

Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.

de Sousa RT, Zanetti MV, Brunoni AR, Machado-Vieira R.

Curr Neuropharmacol. 2015;13(5):616-35.

2.

Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Tundo A, de Filippis R, Proietti L.

World J Psychiatry. 2015 Sep 22;5(3):330-41. doi: 10.5498/wjp.v5.i3.330.

3.

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.

Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P.

Int J Neuropsychopharmacol. 2015 May 25;18(11):pyv060. doi: 10.1093/ijnp/pyv060.

4.

Striatal dopamine D2/3 receptor availability in treatment resistant depression.

de Kwaasteniet BP, Pinto C, Ruhé HG, van Wingen GA, Booij J, Denys D.

PLoS One. 2014 Nov 20;9(11):e113612. doi: 10.1371/journal.pone.0113612. eCollection 2014. Erratum in: PLoS One. 2015;10(8):e0135764. Ruhé, Eric H G [corrected to Ruhé, Henricus G].

5.
6.

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.

Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY.

Braz J Med Biol Res. 2014 Jul;47(7):605-16. Epub 2014 Jun 13. Review.

7.

A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.

Coplan JD, Gopinath S, Abdallah CG, Berry BR.

Front Behav Neurosci. 2014 May 20;8:189. doi: 10.3389/fnbeh.2014.00189. eCollection 2014. Review.

8.

Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.

Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME.

Neuropsychopharmacology. 2014 Oct;39(11):2549-59. doi: 10.1038/npp.2014.101. Epub 2014 May 7.

9.

Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.

Baskaran A, Summers D, Willing SL, Jokic R, Milev R.

Ther Adv Psychopharmacol. 2013 Jun;3(3):139-49. doi: 10.1177/2045125312467348.

10.

A review of antidepressant therapy in primary care: current practices and future directions.

Kennedy SH.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12r01420. doi: 10.4088/PCC.12r01420. Epub 2013 Apr 11.

11.

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes.

Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC.

PLoS Med. 2013;10(3):e1001403. doi: 10.1371/journal.pmed.1001403. Epub 2013 Mar 12.

12.

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.

Gedge L, Lazowski L, Murray D, Jokic R, Milev R.

Neuropsychiatr Dis Treat. 2010 Sep 7;6:501-8.

13.

Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.

Philip NS, Carpenter LL, Tyrka AR, Price LH.

Expert Opin Pharmacother. 2010 Apr;11(5):709-22. doi: 10.1517/14656561003614781. Review.

14.

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D.

J Exp Clin Cancer Res. 2009 Sep 23;28:131. doi: 10.1186/1756-9966-28-131.

15.
16.

Emerging targets for antidepressant therapies.

Rakofsky JJ, Holtzheimer PE, Nemeroff CB.

Curr Opin Chem Biol. 2009 Jun;13(3):291-302. doi: 10.1016/j.cbpa.2009.04.617. Epub 2009 Jun 6. Review.

17.
18.

Novel targets for antidepressant therapies.

Holtzheimer PE, Nemeroff CB.

Curr Psychiatry Rep. 2008 Dec;10(6):465-73. Review.

19.

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.

Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB.

J Psychiatr Res. 2009 Jan;43(3):205-14. doi: 10.1016/j.jpsychires.2008.05.003. Epub 2008 Jun 30.

20.

Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.

Muma NA, Singh RK, Vercillo MS, D'Souza DN, Zemaitaitis B, Garcia F, Damjanoska KJ, Zhang Y, Battaglia G, Van de Kar LD.

Neuropharmacology. 2007 Sep;53(4):552-62. Epub 2007 Jul 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk